How much funding has Intersect ENT raised?

Intersect ENT has raised $60.0M in total funding, most recently a series d round.

Who are Intersect ENT's investors?

Intersect ENT's investors include Medtronic, Kleiner Perkins, Shiv Chaudhary, US Venture Partners.

When was Intersect ENT founded?

Intersect ENT was founded in 2003.

Where is Intersect ENT headquartered?

Intersect ENT is headquartered in Menlo Park, California, United States.

What industry is Intersect ENT in?

Intersect ENT operates in Biotech, Healthcare.

How many employees does Intersect ENT have?

Intersect ENT has 201-500 employees.

Intersect ENT

Acquired

PROPEL™ Sinus Implant

Public · Menlo Park, United States · Founded 2003 · $60.0M raised

Biotech

Healthcare

Headquarters: Menlo Park, California
Employees: 201–500
Founded: 2003
Business Model: B2B
Website: intersectent.com

Total Funding: $60.0M
Last Round: $30.0M Series DFeb 2013
Rounds: 2
Type: Public

About

Intersect ENT was a Menlo Park, California-based medical device company that developed and commercialized drug-eluting sinus implants, including the PROPEL and SINUVA products, designed to improve outcomes for ENT surgical patients. Founded in 2003, it was publicly traded before being acquired by Medtronic in May 2022 for approximately $1.1 billion.

Summary

Intersect ENT is a Biotech company based in Menlo Park, United States, founded in 2003. It has raised $60.0M in total across 2 rounds, most recently a $30.0M Series D round in Feb 2013. Investors include Medtronic, Kleiner Perkins and Shiv Chaudhary.